Canntab Therapeutics Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard C. Goldstein
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 223 Riviera Drive Markham ON Canada L3R 5J6
- IPO Date
- Nov 28, 2017
- Website
- canntab.ca
- Similar Companies
- Business
- Canntab Therapeutics Limited is a Canadian pharmaceutical company specializing in the research, development, and manufacturing of advanced cannabinoid-based oral dosage formulations. The company produces a range of solid oral dose delivery systems including extended release (XR) tablets, instant release (IR) tablets, flash melt tablets, modified release tablets, and bi-layered tablet solutions that provide precise cannabinoid (THC, CBD) and terpenoid blends in exacting dosages. Canntab focuses on pharmaceutical-grade, standardized medical cannabis extracts designed for therapeutic use in treating conditions such as sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, arthritis, pain management, addiction, and appetite loss associated with cancer treatments. Its products are developed to offer enhanced bioavailability, ingredient stability, and customizable dosing, positioning Canntab as a leader in medical oral dose cannabis solutions in North America. Founded in 2016 and headquartered in Markham, Ontario, Canntab operates a fully equipped pharmaceutical-grade manufacturing facility and holds processing and research licenses in cannabis. The company has achieved three patents granted in the United States, Canada, and Australia, with additional patent applications pending internationally, reflecting its proprietary technology in solid oral dosage cannabis formulations. Recent major developments include a strategic operational refocus toward tablet manufacturing and international licensing, prompted by market conditions in the cannabis sector and a crowded pre-roll and vaporizer market. Canntab has raised over CAD 1.3 million through a secured convertible debenture financing to support working capital and corporate needs. It has also entered into agreements for expanding high-end extraction capabilities and fractional distillation to advance product research beyond THC and CBD, into other cannabinoids such as CBN, CBG, and CBC. Additionally, the company is working on partnerships and licensing agreements to commercialize its patented technologies globally. Canntab is listed on the Canadian Securities Exchange under the ticker PILL and on the OTCQB market under CTABF. Canntab serves medical patients primarily in Canada, with an expanding focus on international markets including the United States, Australia, and Asia. The company's products are available on major Canadian cannabis retail platforms including the Ontario Cannabis Store and Nova Scotia Liquor Corporation. In summary, Canntab Therapeutics Limited is a pioneering cannabis pharmaceutical company focused on delivering standardized, precise, and effective medical cannabis oral dosage products, with ongoing strategic efforts to grow through advanced formulation technology, patent protections, and international market expansion.
CSE Bulletin: Delist - Canntab Therapeutics Limited (PILL)
Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order
Canntab Therapeutics seeks to move manufacturing process as Markham lease expires
Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation
Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant
Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
Levitee Labs Teams Up With Canntab Therapeutics, Offer Cannabinoid Products As Alternatives To Opioids
Canntab Therapeutics Completes First Shipment Of THC Tablets To Ontario Cannabis Stores
Levitee Labs partners with Canntab Therapeutics to provide alternative to drugs amid opioid crisis in Canada
Canntab Therapeutics provides an update on its recent product deliveries for Ontario and Australia
Pathway Health and Canntab Therapeutics strike agreement to provide oral tablet cannabinoid products in select Canadian pharmacies
Canntab Therapeutics receives medical sales license from Health Canada for its Ontario facility
Canntab Therapeutics reaches agreement with 36Eight Technologies to provide effective medical solutions for patients
Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.
Dow pulls to above the flatline after morning struggles as traders digest jobs data
Canntab Therapeutics brings in C$1,259,250 gross from early exercise of warrants
Canntab Announces the Early Exercise of $1,259,250 Warrants
Canntab Therapeutics receives export license from Health Canada
Canntab Receives Export License Approval from Health Canada